Essa’s shares tank as it looks for options after abandoning prostate cancer drug

Essa Pharma is exploring “strategic options” as it ends work on its prostate cancer drug that failed a mid-stage test. The company's shares {$EPIX} nosedived by as much as 65% premarket Friday. In a planned ...